惡性腫瘤肥胖患者化學療法藥物劑量計算的研究進展_West China Medical Journal

Authors：

董玲燕 ,  尹如鐵

Corresponding?author：

尹如鐵, Email: 18951670910@189.cn

Keywords：

肥胖; 惡性腫瘤; 化療藥物劑量

DOI：

10.7507/1002-0179.20130297

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

隨著肥胖患者發病率不斷上升，與肥胖相關腫瘤的發病率也持續增高，肥胖不僅給手術帶來困難，同時肥胖患者的化學療法藥物劑量該如何計算更科學，目前還沒有統一的標準。本文就惡性腫瘤肥胖患者化療劑量的研究進展做一綜述。

Citation： 董玲燕,尹如鐵. 惡性腫瘤肥胖患者化學療法藥物劑量計算的研究進展. West China Medical Journal, 2013, 28(6): 944-947. doi: 10.7507/1002-0179.20130297 Copy

1.	Wang YC, Mcpherson K, Marsh T, et al. Health and economic burden of the projected obesity trends in the USA and the UK[J]. Lancet, 2011, 378(9793): 815-825.
2.	Vainio H, Bianchini F. Weight control and physical actrivity in cancer prevention[J]. Obes Rev, 2002, 3(1): 5-8.
3.	Calle EE, Kaaks R. Overweight, obesity and Cancer: epidemiological evidence and proposed mechanisms[J]. Nat Rev Cancer, 2004, 4(8): 579-591.
4.	曹冬焱, 田秦杰. 肥胖與婦科腫瘤[J]. 實用婦產科雜志, 2011, 27(5): 325-326.
5.	Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from Cancer in a prospectively studied cohort of U.S. adults[J]. N Engl J Med, 2003, 348(17): 1625-1638.
6.	Barrett SV, Paul J, Hay A, et al. Does body mass index affect progression-free or overall survival in patients with ovarian Cancer? Results from SCOTROC I trial[J]. Ann Oncol, 2008, 19(5): 898-902.
7.	Pinkel D. The use of body surface area as a criterion of drug dosage in Cancer chemotherapy[J]. Cancer Res, 1958, 18(7): 853-856.
8.	Sawyer M, Ratain MJ. Body surface area as a determinant of pharmacokinetics and drug dosing[J]. Invest New Drugs, 2001, 19(2): 171-177.
9.	Sparreboom A, Wolff AC, Mathijssen RH, et al. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese[J]. J Clin Oncol, 2007, 25(30): 4707-4713.
10.	DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight be known[J]. Arch Intern Med, 1916, 5(5): 303-311.
11.	Kouno T, Katsumata N, Mukai H, et al. Standardization of the body surface area (BSA) formula to calculate the dose of anticancer agents in Japan[J]. Jpn J Clin Oncol, 2003, 33(6): 309-313.
12.	Navarro WH. Impact of obesity in the setting of high-dose chemotherapy[J]. Bone Marrow Transplant, 2003, 31(11): 961-966.
13.	Blouin RA, Warren GW. Pharmacokinetic considerations in obesity[J]. J Pharm Sci, 1999, 88(1): 1-7.
14.	Bargieri JV, Quadros AA, Pereira RD, et al. Basal metabolic rate and body composition in patients with post-polio syndrome[J]. Ann Nutr Metab, 2008, 53(3-4): 199-204.
15.	Gimble JM, Sutton GM, Ptitsyn AA, et al. Circadian rhythms in adipose tissue: an update[J]. Curr Opin Clin Nutr Metab Care, 2011, 14(6): 554-561.
16.	Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy[J]. Clin Pharmacokinet, 2000, 39(3): 215-231.
17.	Abernethy DR, Greenblatt DJ. Drug disposition in obese humans. An update[J]. Clin Pharmacokinet, 1986, 11(3): 199-213.
18.	Thompson LA, Lawson AP, Sutphin SD, et al. Description of current practices of empiric chemotherapy dose adjustment in obese adult patients[J]. J Oncol Pract, 2010, 6(3): 141-145.
19.	Field KM, Kosmider S, Jefford M, et al. Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey[J]. J Oncol Pract, 2008, 4(3): 108-113.
20.	Colleoni M, Li S, Gelber RD, et al. Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index[J]. Lancet, 2005, 366(9491): 1108-1110.
21.	Wright JD, Tian C, Mutch DG, et al. Carboplatin dosing in obese women with ovarian Cancer: a Gynecologic Oncology Group study[J]. Gynecol Oncol, 2008, 109(3): 353-358.
22.	Greenman CG, Jagielski CH, Griggs JJ. Breast Cancer adjuvant chemotherapy dosing in obese patients[J]. Cancer, 2008, 112(10): 2159-2165.
23.	Pavelka JC, Brown RS, Karlan BY, et al. Effect of obesity on survival in epithelial ovarian Cancer[J]. Cancer, 2006, 107(7): 1520-1524.
24.	Joerger M, Huitema AD, van den Bongard DH, et al. Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors[J]. Clin Cancer Res, 2006, 12(7 Pt 1): 2150-2157.
25.	Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with Cancer: American Society of Clinical Oncology clinical practice guideline[J]. J Clin Oncol, 2012, 30(13): 1553-1561.
26.	Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast Cancer chemotherapy: a nationwide study of community practices[J]. J Clin Oncol, 2003, 21(24): 4524-4531.
27.	Lyman GH, Dale DC, Friedberg J, et al. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study[J]. J Clin Oncol, 2004, 22(21): 4302-4311.
28.	Lopes-Serrao MD, Ussery SM, Hall RG 2nd, et al. Evaluation of chemotherapy-induced severe myelosuppression incidence in obese patients with capped dosing[J]. J Oncol Pract, 2011, 7(1): 13-17.
29.	Jenkins P, Elyan S, Freeman S. Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast Cancer[J]. Eur J Cancer, 2007, 43(3): 544-548.
30.	Chambers P, Daniels S, Thompson LC, et al. American society of clinical oncology guideline on weight-based dosing and its impact on trial design[J]. J Clin Oncol, 2012, 30(31): 3897-3898.
31.	Wright JD, Tian C, Mutch DG, et al. Carboplatin dosing in obese women with ovarian Cancer: a Gynecologic Oncology Group study[J]. Gynecol Oncol, 2008, 109(3): 353-358.
32.	Schwartz J, Toste B, Dizon DS. Chemotherapy toxicity in gynecologic cancer patients with a body surface area＞2 m[J]. Gynecol Oncol, 2009, 114(1): 53-56.
33.	Wilkinson GR. Drug metabolism and variability among patients in drug response[J]. N Engl J Med, 2005, 352(21): 2211-2221.
34.	Scripture CD, Figg WD. Drug interactions in Cancer therapy[J]. Nat Rev Cancer, 2006, 6(7): 546-558.
35.	Mathijssen RH, Loos WJ, Verweij J. Determining the best dose for the individual patient[J]. J Clin Oncol, 2011, 29(33): 4345-4346.
36.	Collins JM, Zaharko DS, Dedrick RL, et al. Potential roles for preclinical pharmacology in phase I clinical trials[J]. Cancer Treat Rep, 1986, 70(1): 73-80.
37.	Egorin MJ, Jodrell DI. Utility of individualized carboplatin dosing alone and in combination regimens[J]. Semin Oncol, 1992, 19(1 Suppl 2): 132-138.
38.	Jodrell DI, Egorin MJ, Canetta RM, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian Cancer[J]. Clin Oncol, 1992, 10(4): 520-528.
39.	Marina NM, Rodman JH, Murry DJ, et al. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors[J]. J Natl Cancer Inst, 1994, 86(7): 544-548.
40.	Dees EC, Watkins PB. Role of cytochrome P450 phenotyping in Cancer treatment[J]. J Clin Oncol, 2005, 23(6): 1053-1055.
41.	Okamoto H, Nagatomo A, Kunitoh H, et al. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae[J]. Cancer Chemother Pharmacol, 1998, 42(4): 307-312.
42.	Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group[J]. Lancet Oncol, 2006, 7(5): 379-391.
43.	Einhorn LH. Curing metastatic testicular Cancer[J]. Proc Natl Acad Sci U S A, 2002, 99(7): 4592-4595.

1. 　Wang YC, Mcpherson K, Marsh T, et al. Health and economic burden of the projected obesity trends in the USA and the UK[J]. Lancet, 2011, 378(9793): 815-825.
2. 　Vainio H, Bianchini F. Weight control and physical actrivity in cancer prevention[J]. Obes Rev, 2002, 3(1): 5-8.
3. 　Calle EE, Kaaks R. Overweight, obesity and Cancer: epidemiological evidence and proposed mechanisms[J]. Nat Rev Cancer, 2004, 4(8): 579-591.
4. 　曹冬焱, 田秦杰. 肥胖與婦科腫瘤[J]. 實用婦產科雜志, 2011, 27(5): 325-326.
5. 　Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from Cancer in a prospectively studied cohort of U.S. adults[J]. N Engl J Med, 2003, 348(17): 1625-1638.
6. 　Barrett SV, Paul J, Hay A, et al. Does body mass index affect progression-free or overall survival in patients with ovarian Cancer? Results from SCOTROC I trial[J]. Ann Oncol, 2008, 19(5): 898-902.
7. 　Pinkel D. The use of body surface area as a criterion of drug dosage in Cancer chemotherapy[J]. Cancer Res, 1958, 18(7): 853-856.
8. 　Sawyer M, Ratain MJ. Body surface area as a determinant of pharmacokinetics and drug dosing[J]. Invest New Drugs, 2001, 19(2): 171-177.
9. 　Sparreboom A, Wolff AC, Mathijssen RH, et al. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese[J]. J Clin Oncol, 2007, 25(30): 4707-4713.
10. 　DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight be known[J]. Arch Intern Med, 1916, 5(5): 303-311.
11. 　Kouno T, Katsumata N, Mukai H, et al. Standardization of the body surface area (BSA) formula to calculate the dose of anticancer agents in Japan[J]. Jpn J Clin Oncol, 2003, 33(6): 309-313.
12. 　Navarro WH. Impact of obesity in the setting of high-dose chemotherapy[J]. Bone Marrow Transplant, 2003, 31(11): 961-966.
13. 　Blouin RA, Warren GW. Pharmacokinetic considerations in obesity[J]. J Pharm Sci, 1999, 88(1): 1-7.
14. 　Bargieri JV, Quadros AA, Pereira RD, et al. Basal metabolic rate and body composition in patients with post-polio syndrome[J]. Ann Nutr Metab, 2008, 53(3-4): 199-204.
15. 　Gimble JM, Sutton GM, Ptitsyn AA, et al. Circadian rhythms in adipose tissue: an update[J]. Curr Opin Clin Nutr Metab Care, 2011, 14(6): 554-561.
16. 　Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy[J]. Clin Pharmacokinet, 2000, 39(3): 215-231.
17. 　Abernethy DR, Greenblatt DJ. Drug disposition in obese humans. An update[J]. Clin Pharmacokinet, 1986, 11(3): 199-213.
18. 　Thompson LA, Lawson AP, Sutphin SD, et al. Description of current practices of empiric chemotherapy dose adjustment in obese adult patients[J]. J Oncol Pract, 2010, 6(3): 141-145.
19. 　Field KM, Kosmider S, Jefford M, et al. Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey[J]. J Oncol Pract, 2008, 4(3): 108-113.
20. 　Colleoni M, Li S, Gelber RD, et al. Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index[J]. Lancet, 2005, 366(9491): 1108-1110.
21. 　Wright JD, Tian C, Mutch DG, et al. Carboplatin dosing in obese women with ovarian Cancer: a Gynecologic Oncology Group study[J]. Gynecol Oncol, 2008, 109(3): 353-358.
22. 　Greenman CG, Jagielski CH, Griggs JJ. Breast Cancer adjuvant chemotherapy dosing in obese patients[J]. Cancer, 2008, 112(10): 2159-2165.
23. 　Pavelka JC, Brown RS, Karlan BY, et al. Effect of obesity on survival in epithelial ovarian Cancer[J]. Cancer, 2006, 107(7): 1520-1524.
24. 　Joerger M, Huitema AD, van den Bongard DH, et al. Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors[J]. Clin Cancer Res, 2006, 12(7 Pt 1): 2150-2157.
25. 　Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with Cancer: American Society of Clinical Oncology clinical practice guideline[J]. J Clin Oncol, 2012, 30(13): 1553-1561.
26. 　Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast Cancer chemotherapy: a nationwide study of community practices[J]. J Clin Oncol, 2003, 21(24): 4524-4531.
27. 　Lyman GH, Dale DC, Friedberg J, et al. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study[J]. J Clin Oncol, 2004, 22(21): 4302-4311.
28. 　Lopes-Serrao MD, Ussery SM, Hall RG 2nd, et al. Evaluation of chemotherapy-induced severe myelosuppression incidence in obese patients with capped dosing[J]. J Oncol Pract, 2011, 7(1): 13-17.
29. 　Jenkins P, Elyan S, Freeman S. Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast Cancer[J]. Eur J Cancer, 2007, 43(3): 544-548.
30. 　Chambers P, Daniels S, Thompson LC, et al. American society of clinical oncology guideline on weight-based dosing and its impact on trial design[J]. J Clin Oncol, 2012, 30(31): 3897-3898.
31. 　Wright JD, Tian C, Mutch DG, et al. Carboplatin dosing in obese women with ovarian Cancer: a Gynecologic Oncology Group study[J]. Gynecol Oncol, 2008, 109(3): 353-358.
32. 　Schwartz J, Toste B, Dizon DS. Chemotherapy toxicity in gynecologic cancer patients with a body surface area＞2 m[J]. Gynecol Oncol, 2009, 114(1): 53-56.
33. 　Wilkinson GR. Drug metabolism and variability among patients in drug response[J]. N Engl J Med, 2005, 352(21): 2211-2221.
34. 　Scripture CD, Figg WD. Drug interactions in Cancer therapy[J]. Nat Rev Cancer, 2006, 6(7): 546-558.
35. 　Mathijssen RH, Loos WJ, Verweij J. Determining the best dose for the individual patient[J]. J Clin Oncol, 2011, 29(33): 4345-4346.
36. 　Collins JM, Zaharko DS, Dedrick RL, et al. Potential roles for preclinical pharmacology in phase I clinical trials[J]. Cancer Treat Rep, 1986, 70(1): 73-80.
37. 　Egorin MJ, Jodrell DI. Utility of individualized carboplatin dosing alone and in combination regimens[J]. Semin Oncol, 1992, 19(1 Suppl 2): 132-138.
38. 　Jodrell DI, Egorin MJ, Canetta RM, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian Cancer[J]. Clin Oncol, 1992, 10(4): 520-528.
39. 　Marina NM, Rodman JH, Murry DJ, et al. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors[J]. J Natl Cancer Inst, 1994, 86(7): 544-548.
40. 　Dees EC, Watkins PB. Role of cytochrome P450 phenotyping in Cancer treatment[J]. J Clin Oncol, 2005, 23(6): 1053-1055.
41. 　Okamoto H, Nagatomo A, Kunitoh H, et al. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae[J]. Cancer Chemother Pharmacol, 1998, 42(4): 307-312.
42. 　Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group[J]. Lancet Oncol, 2006, 7(5): 379-391.
43. 　Einhorn LH. Curing metastatic testicular Cancer[J]. Proc Natl Acad Sci U S A, 2002, 99(7): 4592-4595.

Previous Article
甲氨蝶呤治療類風濕性關節炎的不良反應及應對措施
Next Article
白細胞介素-35在自身免疫性疾病中的研究進展

West China Medical Journal

惡性腫瘤肥胖患者化學療法藥物劑量計算的研究進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content